NCI National Clinical Trials Network-Network Lead Academic Participating Site

描述（由申请人提供）：韦恩州立大学（WSU）- Karmanos癌症研究所（KCI）自1972年以来一直是一个活跃的机构成员办公室合作组系统，自1978年以来一直是NCI指定的综合癌症中心，自1993年以来一直是一个母机构I期（U 01），自2000年以来一直是一个I期联盟（N 01）的成员。我们是西南肿瘤学组（SWOG）、放射肿瘤学组（RTOG）和妇科肿瘤学组（GOG）的积极成员，并通过CTSU网络参与ACRIN、ACOSOG、NSABP和组间试验。在过去的四十年里，我们已经招募了5,500多名患者参加合作组临床试验，自2007年以来，已经招募了600多名患者参加治疗性和非治疗性试验，以一致的方式达到并超过了累积目标。我们的癌症中心是一个独特的城市研究，患者护理和教育中心，这反映在我们招募少数民族（24%）和妇女（52%）参加治疗合作组试验。自2009年以来，所有成人合作团体资格的第二阶段和第一阶段方案都已通过CIRB提交激活。多年来，我们的教职员工在合作团体的行政和科学职能方面发挥了重要作用。目前，六名教师担任十个关键领导职务。自2007年以来，25名教师已研究或合作研究者的121个合作组摘要或手稿，和18名教师已PI或合作PI的43个合作组研究。自成立以来，WSU/KCI的癌症项目已被组织为多学科疾病项目，其前提是多学科临床研究和护理为癌症患者提供最佳治疗选择。因此，将想法转化为合作小组的建议和研究，并将NCI指定的高优先级试验纳入WSU/KCI治疗优先事项，这很容易促进。NCI资助的试验在我们机构内具有最高的激活优先级。Lawrence Flaherty博士（自1988年起为SWOG成员，自1996年起为SWOG U-10 PI）将担任本申报资料的PI。他从1990年到2011年担任SWOG黑色素瘤副主席，自2011年以来一直担任SWOG数据安全和监测委员会主席。

DESCRIPTION (provided by applicant): Wayne State University (WSU) - Karmanos Cancer Institute (KCI) has been an active institutional member office cooperative group system since 1972, an NCI designated Comprehensive Cancer Center since 1978, a parent institution Phase I (U01) since 1993, and a member of a Phase 1 consortium (N01) since 2000. We have an active membership in the Southwest Oncology Group (SWOG), Radiation Oncology Group (RTOG), and Gynecologic Oncology Group (GOG) with participation in ACRIN, ACOSOG, NSABP, and Intergroup trials through the CTSU network. We have enrolled over 5,500 patients onto cooperative group clinical trials over the past forty years and over 600 patients have been enrolled onto therapeutic and non-therapeutic trials since 2007, meeting and exceeding accrual goals in a consistent manner. Our Cancer Center is a unique urban based center of research, patient care and education which is reflected in our recruitment of minorities (24%) and women (52%) onto therapeutic cooperative group trials. All adult cooperative group qualifying Phase II and 1 protocol have been submitted through the CIRB for activation since 2009. Over the years, our faculty members have played an important role in both the administrative and scientific functions of the cooperative groups. Presently, six faculty members hold ten key leadership positions. Since 2007, 25 faculty members have been investigators or co-investigators of 121 cooperative group abstracts or manuscripts, and 18 faculty members have been PI or Co-PIs of 43 cooperative group studies. Since our inception, the cancer programs of WSU/KCI have been organized as multidisciplinary disease programs built on the premise that multidisciplinary clinical research and care provides the best treatment option for patients with cancer Accordingly, the translation of ideas into cooperative group proposals and studies and the incorporation of NCI designated high-priority trials into the WSU/KCI treatment priorities have been easily facilitated. NCI funded trials have the highest priority for activation within our institution. Dr. Lawrence Flaherty, a SWOG member since 1988 and the SWOG U-10 PI since 1996 will serve as the PI of this submission. He was the SWOG Melanoma vice Chair from 1990 until 2011 and has been Chair of the SWOG Data Safety and Monitoring Committee since 2011.